Hyperfine, Inc.
NASDAQ:HYPRMedical - Devices
+$0.22 today
- Market cap
- $51.10M
- Beta
- 1.38
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.36
Volume 1.16M
Average 0.60M
HYPR Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Hyperfine, Inc.NASDAQ: HYPR
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $8.62M (cash outflow) fell 8.4% year over year, ahead of the -13.7% change in trailing-twelve-month net income. Sequentially, it rose 45.9% from the prior quarter. Over 3 fiscal years it compounded at -21.4% a year.
Context
- Net income amounted to 262.3% of revenue in FY2025, down 53.6 pp from a year earlier.
- Net income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$29.81M (-16.2%) for the fiscal year ending Dec 2026, a slowdown from the -12.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$8.62M+45.9% QoQ
- Last fiscal yearDec 2025
- -$35.57M-12.6% YoY
- LTMMar 2026
- -$34.78M-13.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -8.4% | +3.5% | +12.0 pp |
| 1 year | -12.6% | -16.2% | -3.6 pp |
| 3-year CAGR | -21.4% | -11.1% | +10.3 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (35.57M) USD
- Year-over-year change
- +12.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (35.57M) | +12.6% |
| FY2024 | 2024-12-31 | (40.72M) | +8.0% |
| FY2023 | 2023-12-31 | (44.24M) | +39.5% |
| FY2022 | 2022-12-31 | (73.16M) | -12.8% |
| FY2021 | 2021-12-31 | (64.85M) | — |
Net Income vs competitors
How HYPR compares with its peers on the latest reported figures
- HYPR's LTM Mar 2026 net income of $34.78M is the 5th largest of the 7 companies compared; the peer median is $45.21M.
- Its year-over-year change of -13.7% is the 6th highest of 7, against a peer median of +0.6%.
- Net income amounts to 226.9% of revenue for HYPR, versus a peer median of 61.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | $55.48M | +255.0% | -21.8% | 86687.5% | |
| LTM Mar 2026 | $53.21M | -6.8% | -2.9% | 60.1% | |
| LTM Mar 2026 | $45.34M | -20.5% | +22.1% | 62.7% | |
IMAImageneBio Inc | LTM Mar 2026 | $45.07M | +8.1% | -8.7% | — |
| LTM Mar 2026 | $34.78M | -13.7% | -21.4% | 226.9% | |
| LTM Mar 2026 | $27.09M | +14.1% | +24.2% | — | |
| LTM Mar 2026 | $8.27M | -11.1% | -14.8% | 7.8% | |
| Peer median (excluding HYPR) | $45.21M | +0.6% | -5.8% | 61.4% | |
Competitors are the stored peer set for HYPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (64.85M) | (73.16M) | (44.24M) | (40.72M) | (35.57M) |
| Depreciation & Amortization | 726K | 1.02M | 1.05M | 1.01M | 1.09M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.9M | 10.65M | 4.74M | 4.36M | 2.8M |
| Change in Working Capital | 8.97M | (10.93M) | (3.62M) | (3.62M) | 4.41M |
| Accounts Receivables | 981K | (1.55M) | (1.57M) | (2.77M) | 1.78M |
| Inventory | (2.67M) | (312K) | (2.21M) | 562K | (1.48M) |
| Accounts Payables | 1.44M | (1.57M) | 533K | 382K | 2.43M |
| Other Working Capital | 9.22M | (7.5M) | (365K) | (1.8M) | 1.68M |
| Other Non-Cash Items | 1.07M | 91K | 249K | 204K | (677K) |
| Operating Cash Flow | (47.18M) | (72.34M) | (41.81M) | (38.77M) | (27.95M) |
| Capital Expenditures | (2.71M) | (585K) | (804K) | (383K) | (1.19M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (2.71M) | (585K) | (804K) | (383K) | (1.19M) |
| Debt Repayment | (178K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.5M | 7K | 174K | 848K | 27.5M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 146.48M | 0 | 0 | 171K | 0 |
| Financing Cash Flow | 176.77M | 7K | 174K | 1.02M | 27.5M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 126.87M | (72.92M) | (42.44M) | (38.13M) | (1.63M) |
| Free Cash Flow | (49.89M) | (72.92M) | (42.61M) | (39.15M) | (29.13M) |
Hyperfine, Inc.
NASDAQ:HYPR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.